CFDE Data Portal | Search PCOTH

	Label	Description
	PCOTH Gene (Entity type)	ENSG00000205861 - prostate and testis expressed opposite C1QTNF9B and MIPEP
	GSE226249 pirfenidone HL 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

PCOTH

ENSG00000205861 - prostate and testis expressed opposite C1QTNF9B and MIPEP

GSE226249 pirfenidone HL 0 v 7 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human up

A Gene Set from LINCS

GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn

A Gene Set from LINCS

GSE108464 AZ-628 6 v 15 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 2 v 4 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 8 human dn

A Gene Set from LINCS

GSE261563 CX-5461 3 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.